US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Virtus LifeSci Biotech Products ETF

104.92

+2.922.86%

Post-market: 104.920.00000.00%16:10 EDT

Volume:25.82K

Turnover:2.71M

Market Cap:131.15M

PE:- -

High:105.65

Open:104.03

Low:103.98

Close:102.00

52wk High:110.05

52wk Low:68.05

Shares:1.25M

Float Shares:1.25M

Volume Ratio:2.78

T/O Rate:2.07%

Dividend:- -

Dividend Rate:- -

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Insilico Medicine Surges Over 7% in Morning Trading on New AI Drug Discovery Partnership with CMS

Genetic Technologies Faces ASX Deadlines Amid Long-Term Trading Suspension

ECB Officials Couldn't Overlook Energy Shock in June

Teva Pharmaceuticals Obtains Rights to Commercialize Polpharma's Biosimilar Candidate to Ocrevus

MT Newswires Live

ECB Officials Couldn't Look Through Energy Shock in June

Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis

Satellos Bioscience Posts Encouraging Six-Month TRAILHEAD Data in Adult DMD Patients

Yomiuri: MUFG to Evolve into Growth-oriented Approach, CEO Says

South Korea Anticipates Record Biopharmaceutical Exports for First Half of Year

ImageneBio appoints Matt Robbins as general counsel

HANXBIO-B Forges Strategic Alliance to Pioneer AI-Enhanced Drug Discovery Framework

Novartis agrees to acquire Myricx Bio for up to $1.5B

Bio-Gene Technology to Hold Virtual Extraordinary General Meeting in August

How FDA Priority Review for First-in-Class LGMD Drug BBP-418 Could Impact BridgeBio Pharma (BBIO) Investors

Simply Wall St.

Analyst Lifts BridgeBio Price Target to $98 as BBP‑418 Becomes Core Growth Driver Following Strong Phase 3 Data

BridgeBio Wins FDA Priority Review for BBP-418 Therapy

BridgeBio announces FDA acceptance, priority review of BBP-418 NDA

BridgeBio Announces FDA Acceptance and Priority Review of NDA for BBP-418 for LGMD2I/R9

BridgeBio submits BBP-418 NDA to FDA

BridgeBio Submits NDA to FDA for BBP-418 for Individuals Living with LGMD2I/R9

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.imtigers.com/stock/BBP/news?page=9"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"BBP","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BBP\",,,,,undefined,":{"symbol":"BBP","market":"US","secType":"STK","nameCN":"Virtus LifeSci Biotech Products ETF","latestPrice":104.9185,"timestamp":1789675200000,"preClose":101.9998,"halted":0,"volume":25819,"hourTrading":{"tag":"盘后","latestPrice":104.9185,"preClose":104.9185,"latestTime":"16:10 EDT","volume":7,"amount":734.4295,"timestamp":1789675804633,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.028614761989729405,"floatShares":1250004,"shares":1250004,"eps":0,"marketStatus":"Post-Mkt","change":2.9187,"latestTime":"09-17 16:47:24 EDT","open":104.03,"high":105.65,"low":103.975,"amount":2710829,"amplitude":0.016422,"askPrice":150.54,"askSize":100,"bidPrice":91.28,"bidSize":100,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1789689600000},"marketStatusCode":4,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":101.9998,"sharesOutstanding":600004,"nav":101.285,"aum":121542550.39,"bidAskSpread":0.002402,"preHourTrading":{"tag":"盘前","latestPrice":101.9998,"preClose":101.9998,"latestTime":"07:00 EDT","volume":1,"amount":101.9998,"timestamp":1789642858616,"change":0,"changeRate":0,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":104.9185,"preClose":104.9185,"latestTime":"16:10 EDT","volume":7,"amount":734.4295,"timestamp":1789675804633,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":2.784921,"impliedVol":0.2249,"impliedVolPercentile":0.4343},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BBP\",,,,,undefined,":{"symbol":"BBP","floatShares":1250004,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":2.784921,"shares":1250004,"dividePrice":0,"high":105.65,"amplitude":0.016422,"preClose":101.9998,"low":103.975,"week52Low":68.046,"pbRate":"--","week52High":110.05,"institutionHeld":0,"latestPrice":104.9185,"eps":0,"divideRate":0,"volume":25819,"delay":0,"ttmEps":0,"open":104.03,"prevYearClose":79.9149,"prevWeekClose":103.4597,"prevMonthClose":106.46,"prevQuarterClose":96.2686,"fiveDayClose":103.4736,"twentyDayClose":109.9037,"sixtyDayClose":92.7358},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BBP\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BBP\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BBP\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BBP\",pageSize:20,pageCount:9,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1156997423","title":"Insilico Medicine Surges Over 7% in Morning Trading on New AI Drug Discovery Partnership with CMS","url":"https://stock-news.laohu8.com/highlight/detail?id=1156997423","media":"Deep News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1156997423?lang=en_us&edition=fundamental","pubTime":"2026-07-13 10:10","pubTimestamp":1783908642,"startTime":"0","endTime":"0","summary":"Insilico Medicine (03696) shares rose more than 7% in early trading. At the time of writing, the stock is up 6.21% to HK$45.48, with a turnover of HK$332 million. On July 13th, according to a post on...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AIPO","IE00BYV24P56.USD","00867","CHAT","BK1191","VTHR","IBB","SG9999015978.USD","IE00BVYPNQ40.USD","SG9999015986.USD","ARTY","IE00BGHQDM52.EUR","LFSC","SBIO","BK4585","SG9999004220.SGD","BK4588","GDOC","BK1593","PBE","SG9999015945.SGD","WRND","QTOC","AGIX","IE00BMCWC346.EUR","GSKH","IE00BVYPNP33.GBP","SG9999015952.SGD","LU2488822045.USD","BBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650074239","title":"Genetic Technologies Faces ASX Deadlines Amid Long-Term Trading Suspension","url":"https://stock-news.laohu8.com/highlight/detail?id=2650074239","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650074239?lang=en_us&edition=fundamental","pubTime":"2026-07-10 14:52","pubTimestamp":1783666376,"startTime":"0","endTime":"0","summary":"Genetic Technologies ( ($AU:GTG) ) has shared an update. Genetic Technologies Limited, a biotechnology company specializing in genetic testing and ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/genetic-technologies-faces-asx-deadlines-amid-long-term-trading-suspension?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/genetic-technologies-faces-asx-deadlines-amid-long-term-trading-suspension?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["DARP","JDOC","FHLC","HELX","SYNB","BK4585","AGNG","RSPH","WDNA","IBB","BK4588","BBP","FWD","XT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650927633","title":"ECB Officials Couldn't Overlook Energy Shock in June","url":"https://stock-news.laohu8.com/highlight/detail?id=2650927633","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650927633?lang=en_us&edition=fundamental","pubTime":"2026-07-09 21:41","pubTimestamp":1783604460,"startTime":"0","endTime":"0","summary":"The European Central Bank said it was unable to overlook the energy shock at its meeting in June, when higher energy prices were expected to push inflation above its 2% target over the medium term.The","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MODL","PEVC","AVSD","ILCV","CGDV","EES","EQRR","FLV","FXR","MAPP","IMCG","IDEV","BKDV","CAOS","CLIX","LGH","GSG","CGUI","DFUV","CGUS","VAW","AVIE","ARP","CMCI","MDLV","FXL","BGH","FXD","AVDV","DIVZ","IMOM","HIDV","IUS","LCG","BSR","UCC","DECU","FT","HGER","PRVS","IJK","TXUE","ANEW","ADPV","BBP","BAMA","CMDT","CDC","KOMP","BKCI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650593922","title":"Teva Pharmaceuticals Obtains Rights to Commercialize Polpharma's Biosimilar Candidate to Ocrevus","url":"https://stock-news.laohu8.com/highlight/detail?id=2650593922","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650593922?lang=en_us&edition=fundamental","pubTime":"2026-07-09 21:09","pubTimestamp":1783602548,"startTime":"0","endTime":"0","summary":"Teva Pharmaceutical Industries'  Teva Pharmaceuticals International subsidiary and Polpharma Biologics said Thursday they have signed a global licensing agreement that gives Teva exclusive rights to commercialize Polpharma's proposed biosimilar to multiple sclerosis drug Ocrevus.The licensing agreement covers both the intravenous and subcutaneous formulations of Polpharma's biosimilar candidate, the companies said.Under the agreement, Polpharma Biologics will be responsible for the development and manufacturing of the biosimilar candidate, while Teva will be tasked with regulatory submissions and subsequent commercialization in the US, Europe, Brazil, Canada, Australia, New Zealand, Israel, and Turkey, according to a statement.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4596","BK4007","BK4584","LU2324357040.USD","BBP","BK4585","TEVA","BK4566","BK4557","LU1983299246.USD","BK4588","BK4559"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650924226","title":"ECB Officials Couldn't Look Through Energy Shock in June","url":"https://stock-news.laohu8.com/highlight/detail?id=2650924226","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650924226?lang=en_us&edition=fundamental","pubTime":"2026-07-09 20:55","pubTimestamp":1783601700,"startTime":"0","endTime":"0","summary":"The European Central Bank said it was unable to overlook the energy shock at its meeting in June, when higher energy prices were expected to push inflation above its 2% target over the medium term.The","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TSLT","07366","TLA","CGDV","FXL","TSLQ","EQRR","TSL","CMDT","07766","AVIE","TSLY","BKCI","KOMP","TEST","09366","CMCI","IUS","TSII","TSLL","IDEV","CAOS","VAW","BBP","GSG","TSLS","TSLI","IJK","TSLZ","UCC","AVDV","TSDD","DFUV","TESL","TXUE","TSLW","ANEW","AVSD","CRSH","TSLO","BGH","FXR","CLIX","TSLP","HGER","PEVC","IMOM","TSLG","TSLR","TSYY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650492491","title":"Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2650492491","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650492491?lang=en_us&edition=fundamental","pubTime":"2026-07-09 20:30","pubTimestamp":1783600200,"startTime":"0","endTime":"0","summary":"Teva secures exclusive global rights to commercialize Polpharma Biologics’ biosimilar candidate to Ocrevus (ocrelizumab), including both intravenous and subcutaneous formulations. Agreement advances T","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/09/3324800/0/en/Teva-and-Polpharma-Biologics-Announce-Global-Licensing-Agreement-for-a-Biosimilar-Candidate-to-Ocrevus-ocrelizumab-for-Multiple-Sclerosis.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649999887","title":"Satellos Bioscience Posts Encouraging Six-Month TRAILHEAD Data in Adult DMD Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2649999887","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649999887?lang=en_us&edition=fundamental","pubTime":"2026-07-08 18:57","pubTimestamp":1783508255,"startTime":"0","endTime":"0","summary":"The latest update is out from Satellos Bioscience ( ($TSE:MSCL) ). Satellos Bioscience Inc., a clinical-stage biotechnology company developing the ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/satellos-bioscience-posts-encouraging-six-month-trailhead-data-in-adult-dmd-patients?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/satellos-bioscience-posts-encouraging-six-month-trailhead-data-in-adult-dmd-patients?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XT","BBC","SYNB","BBP","BK4588","BK4585","DARP","AGNG","JDOC","FWD","IBB","RSPH","FHLC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649996223","title":"Yomiuri: MUFG to Evolve into Growth-oriented Approach, CEO Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2649996223","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649996223?lang=en_us&edition=fundamental","pubTime":"2026-07-08 17:58","pubTimestamp":1783504680,"startTime":"0","endTime":"0","summary":"Mitsubishi UFJ Financial Group Inc.  will \"evolve into a growth-oriented approach\" and \"convert challenges into tangible results,\" said President and Group CEO Junichi Hanzawa during an interview with The Yomiuri Shimbun.Hanzawa leads the new management team of the Japanese financial group. The following is excerpted from the interview.The Yomiuri Shimbun: You assumed the post of president  on April 1. What themes are you focusing on?Hanzawa: We need to transform our business portfolio. The area of asset management and investor services is particularly important. It currently accounts for only about 5%-6% of operating profit, so there is still room for growth. We aim to raise that figure to double digits in the future. We are also considering mergers and acquisitions in the United States, or in t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MUFG","ROE","GABF","KCE","BK4207","BBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141237651","title":"South Korea Anticipates Record Biopharmaceutical Exports for First Half of Year","url":"https://stock-news.laohu8.com/highlight/detail?id=1141237651","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1141237651?lang=en_us&edition=fundamental","pubTime":"2026-07-08 13:23","pubTimestamp":1783488181,"startTime":"0","endTime":"0","summary":"Data released by the South Korean government on Wednesday indicates that the country's biopharmaceutical exports for the first half of this year are projected to reach a record high.According to...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBBQ","BBP","MRNX","MRNY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649938286","title":"ImageneBio appoints Matt Robbins as general counsel","url":"https://stock-news.laohu8.com/highlight/detail?id=2649938286","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649938286?lang=en_us&edition=fundamental","pubTime":"2026-07-07 21:16","pubTimestamp":1783430160,"startTime":"0","endTime":"0","summary":"ImageneBio (IMA) announced the appointment of Matt Robbins as general counsel, effective July 7. Robbins joins the clinical-stage biotechnology com...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/imagenebio-appoints-matt-robbins-as-general-counsel-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/imagenebio-appoints-matt-robbins-as-general-counsel-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AGNG","XT","BK4585","BK4588","IMA","BK4007","DARP","FHLC","IBB","JDOC","RSPH","BBC","FWD","SYNB","BBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173871150","title":"HANXBIO-B Forges Strategic Alliance to Pioneer AI-Enhanced Drug Discovery Framework","url":"https://stock-news.laohu8.com/highlight/detail?id=1173871150","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1173871150?lang=en_us&edition=fundamental","pubTime":"2026-07-07 19:12","pubTimestamp":1783422743,"startTime":"0","endTime":"0","summary":"HANXBIO-B has announced a strategic partnership aimed at harnessing the power of artificial intelligence to revolutionize the drug development process.The company has entered into a formal agreement...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LFSC","BK1173","AIPO","BK1161","BK1535","CHAT","IBB","PBE","03378","VTHR","GSKH","AGIX","WRND","BK4588","BK4585","BBP","ARTY","GDOC","QTOC","SBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649212640","title":"Novartis agrees to acquire Myricx Bio for up to $1.5B","url":"https://stock-news.laohu8.com/highlight/detail?id=2649212640","media":"TIPRANKS","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649212640?lang=en_us&edition=fundamental","pubTime":"2026-07-06 17:30","pubTimestamp":1783330213,"startTime":"0","endTime":"0","summary":"Novartis (NVS) announced that it has entered into an agreement to acquire Myricx Bio, a privately held UK-based biotechnology company developing a ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/novartis-agrees-to-acquire-myricx-bio-for-up-to-1-5b-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/novartis-agrees-to-acquire-myricx-bio-for-up-to-1-5b-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00B2B36J28.USD","FHLC","JDOC","FWD","MEDX","BK4007","BK4578","IE00BJJMRZ35.SGD","SYNB","LU0320765489.SGD","PPH","XT","IE00B4R5TH58.HKD","IE0009355771.USD","IE00BFTCPJ56.SGD","BK4585","LU0211331839.USD","BBP","DARP","NVS","RSPH","AGNG","BK4588","LU0070302665.USD","LU0208291251.USD","IE0002141913.USD","IBB","IE00BJT1NW94.SGD","BK4532"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649596643","title":"Bio-Gene Technology to Hold Virtual Extraordinary General Meeting in August","url":"https://stock-news.laohu8.com/highlight/detail?id=2649596643","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649596643?lang=en_us&edition=fundamental","pubTime":"2026-07-06 12:57","pubTimestamp":1783313831,"startTime":"0","endTime":"0","summary":"Bio-Gene Technology Ltd. ( ($AU:BGT) ) has shared an announcement. Bio-Gene Technology Ltd., the ASX-listed biotechnology company, is convening an ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/bio-gene-technology-to-hold-virtual-extraordinary-general-meeting-in-august?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/bio-gene-technology-to-hold-virtual-extraordinary-general-meeting-in-august?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","IBB","FWD","JDOC","BGT","RSPH","SYNB","FHLC","BK4585","XT","DARP","AGNG","BBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641161303","title":"How FDA Priority Review for First-in-Class LGMD Drug BBP-418 Could Impact BridgeBio Pharma (BBIO) Investors","url":"https://stock-news.laohu8.com/highlight/detail?id=2641161303","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641161303?lang=en_us&edition=fundamental","pubTime":"2026-06-05 01:20","pubTimestamp":1780593617,"startTime":"0","endTime":"0","summary":"BridgeBio Pharma announced that the FDA previously accepted and granted Priority Review to its New Drug Application for oral BBP-418 in LGMD2I/R9, setting a PDUFA target action date of November 27, 2026, without planning an advisory committee meeting.\nIf approved, BBP-418 would be the first therapy for LGMD2I/R9 and any limb-girdle muscular dystrophy, potentially qualifying BridgeBio for a Priority Review Voucher and opening up further rare disease development paths.\nWe’ll now examine how...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bbio/bridgebio-pharma/news/how-fda-priority-review-for-first-in-class-lgmd-drug-bbp-418","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bbio/bridgebio-pharma/news/how-fda-priority-review-for-first-in-class-lgmd-drug-bbp-418","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4211","ISBC","BK4588","LABU","BK4505","BBIO","BK4585","BBP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638001639","title":"Analyst Lifts BridgeBio Price Target to $98 as BBP‑418 Becomes Core Growth Driver Following Strong Phase 3 Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2638001639","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638001639?lang=en_us&edition=fundamental","pubTime":"2026-05-28 05:16","pubTimestamp":1779916591,"startTime":"0","endTime":"0","summary":"In a report released today, Sean Laaman from Morgan Stanley maintained a Buy rating on BridgeBio Pharma, with a price target of $98.00. Sean Laaman...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/analyst-lifts-bridgebio-price-target-to-98-as-bbp418-becomes-core-growth-driver-following-strong-phase-3-data-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/analyst-lifts-bridgebio-price-target-to-98-as-bbp418-becomes-core-growth-driver-following-strong-phase-3-data-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638639953","title":"BridgeBio Wins FDA Priority Review for BBP-418 Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2638639953","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638639953?lang=en_us&edition=fundamental","pubTime":"2026-05-28 05:00","pubTimestamp":1779915620,"startTime":"0","endTime":"0","summary":"BridgeBio Pharma ( ($BBIO) ) just unveiled an update. On May 27, 2026, BridgeBio Pharma announced that the U.S. Food and Drug Administration accept...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/bridgebio-wins-fda-priority-review-for-bbp-418-therapy?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/bridgebio-wins-fda-priority-review-for-bbp-418-therapy?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LABU","BK4588","BBP","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638915500","title":"BridgeBio announces FDA acceptance, priority review of BBP-418 NDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2638915500","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638915500?lang=en_us&edition=fundamental","pubTime":"2026-05-27 20:17","pubTimestamp":1779884262,"startTime":"0","endTime":"0","summary":"BridgeBio (BBIO) announced the FDA has accepted for filing its new drug application, or NDA, with Priority Review for oral BBP-418 for the treatmen...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bridgebio-announces-fda-acceptance-priority-review-of-bbp-418-nda-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bridgebio-announces-fda-acceptance-priority-review-of-bbp-418-nda-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","BBIO","BK4505","BBP","BK4139","BK4588","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638021595","title":"BridgeBio Announces FDA Acceptance and Priority Review of NDA for BBP-418 for LGMD2I/R9","url":"https://stock-news.laohu8.com/highlight/detail?id=2638021595","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638021595?lang=en_us&edition=fundamental","pubTime":"2026-05-27 19:30","pubTimestamp":1779881400,"startTime":"0","endTime":"0","summary":"- Accepted for Priority Review with PDUFA target action date of November 27, 2026, and poised to launch upon approval; being granted Priority Review by the FDA reiterates the serious unmet need for tr","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/27/3301817/0/en/BridgeBio-Announces-FDA-Acceptance-and-Priority-Review-of-NDA-for-BBP-418-for-LGMD2I-R9.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BBP","BK4081","EMA","LABU","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623762312","title":"BridgeBio submits BBP-418 NDA to FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2623762312","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623762312?lang=en_us&edition=fundamental","pubTime":"2026-03-30 19:56","pubTimestamp":1774871788,"startTime":"0","endTime":"0","summary":"BridgeBio (BBIO) announced the submission of its new drug application to the FDA for oral BBP-418 for the treatment of individuals living with limb...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bridgebio-submits-bbp-418-nda-to-fda-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bridgebio-submits-bbp-418-nda-to-fda-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BBIO","BBP","BK4505","BK4585","BK4588","BK4139","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623916312","title":"BridgeBio Submits NDA to FDA for BBP-418 for Individuals Living with LGMD2I/R9","url":"https://stock-news.laohu8.com/highlight/detail?id=2623916312","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623916312?lang=en_us&edition=fundamental","pubTime":"2026-03-30 19:30","pubTimestamp":1774870200,"startTime":"0","endTime":"0","summary":"- Comprehensive submission includes interim Phase 3 FORTIFY data demonstrating BBP-418’s rapid, consistent treatment effect and favorable safety profile, with statistically significant and clinically ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/30/3264527/0/en/BridgeBio-Submits-NDA-to-FDA-for-BBP-418-for-Individuals-Living-with-LGMD2I-R9.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LABU","BBP","EMA","BK4081","BK4588"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":9,"pageCount":9,"totalSize":180,"code":"91000000","status":"200"}]}}